Psoriatic Arthritis (PsA) Treatment Market Opportunities 2018 - 2028 | Pfizer Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Eli Lilly & Co, Novartis AG

Nearly 70% of the psoriasis patient population is prone to psoriatic arthritis, and up to 20% of arthritis patients are susceptible to acquire psoriasis, according to the recent findings of the Arthritis Foundation.

The rate of increasing burden of psoriasis and psoriatic arthritis on healthcare industry has been boosting clinical research in the field of psoriatic arthritis, in recent years.

Sustained adoption of conventional disease modifying anti-rheumatic drugs (DMARDs), especially in cost sensitive regions, is projected to push the demand for psoriatic arthritis treatment in coming years.

Get Sample Copy of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2718

Role of Strong Product Pipeline & Mounting Clinical Research Investments

Over 20 drugs for psoriasis and psoriatic arthritis are currently in the phase II of pipeline, whereas more than 28 are in phase III of clinical trial, as indicated by the National Psoriasis Foundation. However, around 24 drugs have already received FDA approval for inclusion in the treatment for psoriasis and psoriatic arthritis.

While such a strong product pipeline continues to drive the demand for psoriasis and psoriatic arthritis treatment, a new research points to the shifting focus of several drug manufacturers to competitive pricing strategies, in an effort to attain widespread acceptance in coming years. Recently, Future Market Insights released a new intelligence based on the analysis of global psoriatic arthritis treatment market. The study forecasts a robust over-7% yearly growth for the market in 2019.

Industry Behemoths Cover More than 55% Market Value Share

In a fairly consolidated global landscape of psoriatic arthritis treatment market, more than 55% share of the total revenue is accounted by industry giants such as Novartis AG and AbbVie Inc. that include biologics in their core portfolio. While market leaders are maintaining focus on FDA approvals and clinical trials, research also points to the increasing importance of diverse pricing strategies.

Moreover, prominent players in psoriatic arthritis treatment market are likely to augment investments in R&D of biosimilars, biologics, and TNF (tumor necrosis factor) inhibitors to target regional markets. A number of leading drug manufacturers are also maintaining sizable investments in DMARDs that are scheduled for market entry in next few years. This is perceived as a strong factor improving growth prospects of psoriatic arthritis treatment market, according to the report.

Besides all these, strategic acquisitions, partnerships, and collaborations will remain the preferred expansion strategies adopted by a majority of prominent operators in psoriatic arthritis treatment landscape,” says a senior research analyst at the company.

Demand for Biologics & DMARDs Gaining Momentum

Research-driven understanding of the pathophysiology of psoriatic arthritis is fueling the introduction of innovative therapies in psoriatic arthritis treatment market, triggering innovations among the market participants – thereby supporting the growth of psoriatic arthritis treatment market. Targeted biological therapy has been demonstrating a decent success rate in terms of inducing temporary pain relief resultant of psoriatic arthritis, and thus continues to represent an attractive position in the psoriatic arthritis treatment market.

The report says that the demand for biologics accounts for more than 55% share of the global market revenue, whereas DMARDs demand makes up for more than 3/4th of the total market value. Although a majority of psoriatic arthritis patients opt for injectable as a preferred route of administration of psoriatic arthritis treatment, increasing introduction of innovative oral drugs is uplifting the popularity of orally administered psoriatic arthritis treatment.

Request Customized Copy of Report @ https://www.futuremarketinsights.com/customization-available/rep-gb-2718

Development of novel oral treatments for psoriatic arthritis is likely to favor the growth of North America’s market. Growing availability of combination therapies and relatively economical biosimilar antibody therapeutics are identified to be the primary boosters for the growth of Europe’s market. Collectively, North America and Europe account for over 60% share in the global value of psoriatic arthritis treatment market. The report indicates that the psoriatic arthritis market in Asia Pacific is likely to display high growth potential in the course of next few years.

Psoriatic Arthritis Psa Treatment Market Reports - Table of Contents
Executive Summary

Market Overview

Market Analysis

FMI Analysis and Recommendations

Wheel of Fortune

Market Introduction

Market Taxonomy

Market Definition

Global Psoriatic Arthritis Treatment Market Opportunity Analysis

Macro-Economic Factors

Opportunity Analysis

Market Background

Market Dynamics

Drivers

Restraints

Trends

Key Inclusions

Regulatory Scenario

Pipeline Analysis

North America Psoriatic Arthritis Treatment Market Analysis 2013-2017 and Forecast 2018–2028

Introduction

Historical Market Size (US$ Mn) Analysis By Country, 2013-2017

U.S.

Canada

Market Size (US$ Mn) Forecast By Country, 2018–2028

Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2017

Nonsteriodal Anti-inflammatory Drugs

Disease Modifying Antirheumatic Drugs

Corticosteriods

Antimalarials

Methotrexate

Others

Biologics

TNF Inhibitors

Interleukin Inhibitors

Market Size (US$ Mn) Forecast By Product Type, 2018–2028

Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2017

Oral

Injectable

Market Size (US$ Mn) Forecast By Route of Administration, 2018–2028

Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

Hospital Pharmacies

Retail Pharmacies

Mail Order Pharmacies

Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

Market Attractiveness Analysis

By Country

By Product Type

By Route of Administration

By Distribution Channel

Drivers and Restraints: Impact Analysis

Latin America Psoriatic Arthritis Treatment Market Analysis 2013-2017 and Forecast 2018–2028

Introduction

Historical Market Size (US$ Mn) Analysis By Country, 2013-2017

Brazil

Mexico

Rest of Latin America

Market Size (US$ Mn) Forecast By Country, 2018–2028

Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2017

Nonsteriodal Anti-inflammatory Drugs

Disease Modifying Antirheumatic Drugs

Corticosteriods

Antimalarials

Methotrexate

Others

Biologics

TNF Inhibitors

Interleukin Inhibitors

Browse Report Overview: https://www.futuremarketinsights.com/reports/psoriatic-arthritis-psa-treatment-market

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Blog: http://www.keepfacts.com/

Web: https://www.futuremarketinsights.com/

This release was published on openPR.